Moderna announces recent progress in its immuno-oncology and rare disease programmes and highlights corporate objectives

Source: CBNB


Source: Company press release, 8 Jan 2019 , 8 Jan 2019 , Website: Moderna Inc, a clinical stage biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new generation of
transformative medicines for patients, on 8 Jan 2018 announced recent
updates to several of its immuno-oncology and rare disease programmes and
outlined its 2019-2020 corporate objectives. Moderna has 21 mRNA development
candidates in its pipeline, with 11 programmes now in clinical development.
Based on previously reported clinical observations in two patients with
advanced ovarian carcinoma in its Phase 1 study, Moderna has submitted an
Investigational New Drug (IND) amendment to the US Food and Drug
Administration (FDA) and to the study's clinical research sites to commence
a Phase 2 cohort of mRNA-2416 as a monotherapy in advanced ovarian carcinoma
within its current Phase 1 study. Thus far, 28 patients have been dosed in
the ongoing Phase 1 trial for mRNA-2416, an open-label, multicentre study of
repeated intratumoral injections of mRNA-2416 in patients with advanced
relapsed/refractory solid tumour malignancies and lymphomas. Initial data
from the Phase 1 study were presented in a poster session at the Annual
Meeting of the Society for Immunotherapy of Cancer in Nov 2018. Moderna has
dosed the first patient in the Phase 1 study of mRNA-2752, an intratumoral
injection comprising three mRNAs encoding for OX40L + IL23 + IL36y for the
treatment of advanced or metastatic solid tumour malignancies or lymphoma.
The open label, multicentre study is evaluating the safety and tolerability
of mRNA-2752 as a single agent and in combination either with AstraZeneca's
durvalumab or tremelimumab, and will assess antitumour activity, protein
expression in tumours and pharmacokinetics, and exploratory endpoints that
include assessment of immunological response. Other Moderna studies are
described. Original Source: Moderna Inc, 2019. From website: Released to ICIS 12 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey,, +44 (0) 1223 463167]